IP Library › Granted Patent US 12,590,311
Granted Patent B2
US 12,590,311 · App. 17/619,712 · Granted Mar 31, 2026

Methods and compositions for the treatment of cancer

Inventors: Judy Lieberman (Brookline, MA); Ying Zhang (Boston, MA)
C12N15/115A61K35/00A61K47/10C12N15/1138C12N2310/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,590,311
App. No.
17/619,712
Granted
Mar 31, 2026
Kind
B2
Abstract

The technology described herein is directed to improved chimeric molecules for, e.g, the treatment of cancer. As described herein, the inventors have developed novel chimeric aptamer-siRNA molecules (AsiCs) which demonstrate improved efficacy over existing AsiCs and which can successfully synergize in treating cancer. These AsiC's target cancer cell markers to direct therapeutic siRNA molecules specifically to cancer cells, increasing delivery efficacy and therapeutic effectiveness while reducing the potential for side effects.

Claims (25)

1 . A pharmaceutical composition, kit, or combination comprising at least two different chimeric molecules,

wherein each chimeric molecule comprises an EpCAM-binding aptamer domain and an inhibitory nucleic acid domain comprising an siRNA which inhibits the expression of a gene selected from the group consisting of:

CD47; UPF2; PD-L1; and MCL1;

wherein the at least two different chimeric molecules collectively comprise inhibitory nucleic acid domains that inhibit the expression of each of CD47; UPF2; PD-L1; and MCL1.

2 . The pharmaceutical composition, kit, or combination of claim 1 , wherein the at least two different chimeric molecules collectively comprise inhibitory nucleic acid domains that inhibit the expression of each of:

CD47; UPF2; PARP1; APE1; PD-L1; and MCL1.

3 . The pharmaceutical composition, kit, or combination of claim 1 , wherein the inhibitory nucleic acid specifically binds to a gene product of the selected gene.

4 . The pharmaceutical composition, kit, or combination of claim 1 , wherein the EpCam-binding aptamer domain comprises the sequence of any of SEQ ID NOs: 63-68.

5 . The pharmaceutical composition, kit, or combination of claim 1 , wherein at least one of the inhibitory nucleic acid domains comprises a sequence selected from SEQ ID NOs: 1-11, 26-37, 69-80, 93-102, 149-151, and 158-162, or the reverse complement thereof.

6 . The pharmaceutical composition, kit, or combination of claim 1 , wherein at least one of the chimeric molecules comprises a first and at least one further inhibitory nucleic acid domain.

7 . The pharmaceutical composition, kit, or combination of claim 6 , wherein the first and at least one further inhibitory nucleic acid domains comprise different sequences but each inhibit the expression of the same gene.

8 . The pharmaceutical composition, kit, or combination of claim 6 , wherein the first and at least one further inhibitory nucleic acid domains each inhibit the expression of a different gene.

9 . The pharmaceutical composition, kit, or combination of claim 8 , wherein the at least a second inhibitory nucleic acid domain inhibits the expression of a gene selected from the group consisting of:

PLK1 and MCL1.

10 . The pharmaceutical composition, kit, or combination of claim 1 , comprising the sequence of one of SEQ ID NOs: 127-137 or 163-168.

11 . The pharmaceutical composition, kit, or combination of claim 1 , wherein at least one of the chimeric molecules is conjugated or bound to a cholesterol, a PEG, or a liposome.

12 . The pharmaceutical composition, kit, or combination of claim 1 , wherein at least one of the chimeric molecules further comprises a chemotherapeutic agent.

13 . The pharmaceutical composition, kit, or combination of claim 1 , wherein at least two of the chimeric molecules have different aptamer domains.

14 . The pharmaceutical composition, kit, or combination of claim 1 , further in combination with an immune checkpoint inhibitor.

15 . A method of treating cancer in a subject in need thereof, the method comprising administering a pharmaceutical composition, kit, or combination of claim 1 to the subject.

16 . The method of claim 15 , wherein the cancer is an epithelial cancer, breast cancer, or colon cancer.

17 . The method of claim 16 , wherein the breast cancer is a HER2+ or triple-negative breast cancer (TNBC).

18 . The pharmaceutical composition, kit, or combination of claim 1 , wherein at least one of the at least two different chimeric molecules comprises dTdT.

19 . The pharmaceutical composition, kit, or combination of claim 1 , wherein at least one of the at least two different chimeric molecules comprises one or more of a 2′-F pyrimidine, 2′ sugar modification, a phosphothiorate backbone modification, and a 5′ unlocked nucleic acid modification.

20 . The pharmaceutical composition, kit, or combination of claim 1 , wherein at least one of the at least two different chimeric molecules is conjugated or bound to a cholesterol, a PEG, or a liposome.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 19, 2024
From: BOSTON CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066356/0392 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2022
From: LIEBERMAN, JUDY; ZHANG, YING
To: THE CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 059897/0345 →
Continuity (2)
Provisional Application 62864726 · Jun 21, 2019
Related Publication 20220340906A1 · Oct 27, 2022
References Cited (60)
US 20050147593A1 · Kinch · 2005 [cited by applicant]
US 20070093653A1 · Khvorova et al. · 2007 [cited by applicant]
US 20120014875A1 · Giangrande et al. · 2012 [cited by applicant]
US 20120263740A1 · Gilboa et al. · 2012 [cited by applicant]
US 20150197755A1 · Duan · 2015 [cited by applicant]
US 20170275629A1 · Lieberman et al. · 2017 [cited by applicant]
US 20180105815A1 · Liu · 2018 [cited by applicant]
US 20180171337A1 · O'Neill et al. · 2018 [cited by applicant]
US 20190151469A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
CN 101766817A · 2010 [cited by applicant]
CN 103977433A · 2014 [cited by applicant]
JP 2017526367A · 2017 [cited by applicant]
WO 2010017319A2 · 2010 [cited by applicant]
WO 2010019446A1 · 2010 [cited by applicant]
WO 2011005566A2 · 2011 [cited by applicant]
WO 2011130458A2 · 2011 [cited by applicant]
WO 2011142970A2 · 2011 [cited by applicant]
WO 2012078637A2 · 2012 [cited by applicant]
WO 2013025930A1 · 2013 [cited by applicant]
WO 2014019025A1 · 2014 [cited by applicant]
WO 2014068408A2 · 2014 [cited by applicant]
WO 2014093698A1 · 2014 [cited by applicant]
WO 2014126160A1 · 2014 [cited by applicant]
WO 2016033472A1 · 2016 [cited by applicant]
WO 2016127216A1 · 2016 [cited by applicant]
WO 2018213791A1 · 2018 [cited by applicant]
Lian et al., EBioMedicine vol. 42:281-295, Mar. 14, 2019. [cited by examiner]
Aliabadi et al., “Effective response of doxorubicin-sensitive and-resistant breast cancer cells to combinational siRNA therapy.” Journal of Controlled Release 172(1):219-228 (2013). [cited by applicant]
Burnett et al., “RNA-based therapeutics: current progress and future prospects.” Chemistry & Biology 19(1):60-71 (2012). [cited by applicant]
Dassie et al., “Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.” Nature Biotechnology 27(9):839-849 (2009). [cited by applicant]
Fox et al., “Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application.” Biochemical and Biophysical Research… [cited by applicant]
Gilboa-Geffen et al., “Abstract CN01-02: Targeting basal-like TNBCs and epithelial tumor-initiating cells with aptamer-siRNA chimeras”, Molecular Cancer Therapeutics 12(11 Suppl): (2013). (2 pages). [cited by applicant]
Gilboa-Geffen et al., “Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells.” Molecular Cancer Therapeutics 14(10):2279-2291 (2015). [cited by applicant]
Kim et al., “In Vitro Selection of RNA Aptamer and Specific Targeting of ErbB2 in Breast Cancer Cells.” Nucleic Acid Therapeutics 21(3):173-178 (2011). [cited by applicant]
Machine translation of CN 101766817 A. [cited by applicant]
McNamara et al., “Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.” Nature Biotechnology 24(8):1005-1015 (2006). [cited by applicant]
McNamara et al., “Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.” The Journal of Clinical Investigation 118(1):376-386 (2008). [cited by applicant]
Neff et al., “An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4+ T cell decline in humanized mice.” Science Translational Medicine 3(66ra6):1-27 (2011). [cited by applicant]
Pastor et al. “Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.” Molecular Therapy 19(10):1878-1886 (2011). [cited by applicant]
Pastor et al., “Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay.” Nature 465(7295):227-230 (2010). [cited by applicant]
Petrocca et al., “A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.” Cancer Cell 24(2):182-196 (2013). [cited by applicant]
Rockey et al., “Rational Truncation of an RNA Aptamer to Prostate-Specific Membrane Antigen Using Computational Structural Modeling.” Nucleic Acid Therapeutics 21(5):299-314 (2011). [cited by applicant]
Shigdar et al., “RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule.” Cancer Science 102(5):991-998 (2011). [cited by applicant]
Subramanian et al., “EpCAM aptamer-siRNA chimera targets and regress epithelial cancer.” PloS One 10(7):e0132407 (2015). [cited by applicant]
Thiel et al., “Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.” Nucleic Acids Research 40(13):6319-6337 (2012). [cited by applicant]
Wheeler et al., “Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras.” Molecular Therapy 21(7):1378-1389 (2013). [cited by applicant]
Wheeler et al., “Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.” The Journal of Clinical Investigation 121(6):2401-2412 (2011). [cited by applicant]
Yang et al., “Wnt modulates MCL1 to control cell survival in triple negative breast cancer.” BMC Cancer 14(124):1-13 (2014). [cited by applicant]
Zhang et al., “Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.” Stem Cells Translational Medicine 2(3):233-242 (2013). [cited by applicant]
Zhou et al., “Aptamer-targeted cell-specific RNA interference.” Silence 1(4):1-10 (2010). [cited by applicant]
Zhou et al., “Cell-specific aptamer-mediated targeted drug delivery.” Oligonucleotides 21(1):1-10 (2011). [cited by applicant]
Zhou et al., “Cell-type-specific, aptamer-functionalized agents for targeted disease therapy.” Molecular Therapy—Nucleic Acids 3(6):e169 (2014). [cited by applicant]
Zhou et al., “Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.” Molecular Therapy 16(8):1481-1489 (2008). [cited by applicant]
Zhou et al., “Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.” Nucleic Acids Research 37(9):3094-3109 (2009). [cited by applicant]
Lai et al. “PARP1-siRNA suppresses human prostate cancer cell growth and progression.” Oncol Rep 39(4):1901-1909 (2018). [cited by applicant]
Maire et al. “Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.” Cancer Research 73(2): 813-823 (2013). [cited by applicant]
Takai et al. “Polo-like kinases (Plks) and cancer.” Oncogene 24(2):287-291 (2005). [cited by applicant]
Wang et al. “Intravenous Delivery of sIRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis.” Mol Ther 21(10):1919-1929 (2013). [cited by applicant]
Subramanian et al., “Targeting cancer cells using LNA-modified aptamer-siRNA chimeras.” nucleic acid therapeutics 25.6: 317-322 (2015). [cited by applicant]
Wang et al., “EpCAM aptamer-mediated survivin silencing sensitized cancer stem cells to doxorubicin in a breast cancer model.” Theranostics 5.12: 1456 (2015). [cited by applicant]